Rate Video

ESMO 2022 | Advances in immunotherapy for non-melanoma skin cancer

Paolo Ascierto • 12 Sep 2022

Merkel Cell Carcinoma Skin Cancer

Immuno-Oncology

Paolo Ascierto, MD, National Tumor Institute Fondazione G. Pascale, Naples, Italy, discusses recent advances in immunotherapy for merkel cell carcinoma, cutaneous squamous cell carcinoma, and basal cell carcinoma. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Novel agent combination therapies in melanoma: talimogene laherparepvec, PV-10 & IMO-2125

Paolo Ascierto • 1 Jun 2018

Safety and efficacy of increased ipilimumab dosage in metastatic melanoma

Paolo Ascierto • 7 Oct 2016

BRAF-positive melanoma: what's new?

Paolo Ascierto • 19 Oct 2018

Promising biomarkers to select patients for checkpoint inhibitor therapy in melanoma

Paolo Ascierto • 26 Jan 2017

Related Videos

Adipocytes in the tumor microenvironment: an emerging target for melanoma treatment

Addressing drug resistance and unresponsiveness in melanoma

Producing patient-specific tumor-reactive T-cells

Chiara Cattaneo

Opportunities and challenges in immuno-oncology